Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

scientific article published on 12 January 2017

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2016-10-747170
P932PMC publication ID5374291
P698PubMed publication ID28082441

P50authorRichard A. LarsonQ41899936
Martin S. TallmanQ69035242
Frederick R. AppelbaumQ75025725
Megan OthusQ75025967
Mark R LitzowQ87294607
Peter H. WiernikQ100309276
P2093author name stringBayard L Powell
Jacob M Rowe
Richard Stone
Dan Douer
Jae H Park
Steven Coutre
Harry Erba
Susan Geyer
Debra A Goldman
Sean M Devlin
Marnie Collins
Kristina Laumann
Diana Zannino
Eytan M Stein
Simon Mantha
Ju-Whei Lee
Harry J Iland
P2860cites workA randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL GroupQ28141496
All-trans-retinoic acid in acute promyelocytic leukemiaQ28250406
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcomeQ33389149
Retinoic acid and arsenic trioxide for acute promyelocytic leukemiaQ33409020
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapyQ33781722
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceQ34088767
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.Q34155766
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenanceQ34169298
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.Q34310859
Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemiaQ34508552
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaQ35717816
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidQ37216174
Acute promyelocytic leukemia: what is the new standard of care?Q38238284
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.Q40190940
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.Q40429557
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.Q43278789
Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological studyQ44333428
Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemiaQ44674591
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patientsQ45021199
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.Q51474049
Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia.Q53194151
AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot studyQ71228939
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed OncoloQ73555315
Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study GroupQ74082941
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcomeQ79619548
Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patientsQ81770481
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Q84416493
P433issue13
P407language of work or nameEnglishQ1860
P921main subjectleukemiaQ29496
acute promyelocytic leukemiaQ612108
P304page(s)1763-1767
P577publication date2017-01-12
P1433published inBloodQ885070
P1476titleDeterminants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
P478volume129

Reverse relations

cites work (P2860)
Q90014050Acute Promyelocytic Leukemia in Children: A Single Centre Experience from Turkey
Q98183404Advances in the management of coagulopathy in acute promyelocytic leukemia
Q91979072Bleeding Disorders Associated with Cancer
Q47757780Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Q92276384Complications and management of coagulation disorders in leukemia patients
Q93113343Corpus Callosum Bleed: A Rare Presentation of Acute Promyelocytic Leukemia
Q87865886Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study
Q47569519Melatonin: does it have utility in the treatment of haematological neoplasms?
Q90358835The Factors Affecting Early Death in Newly Diagnosed APL Patients
Q52725967Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin.

Search more.